Amgen Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert A. Bradway
- Full Time Employees
- 28,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Amgen Center Drive Thousand Oaks CA United States of America 91320-1799
- IPO Date
- Jun 17, 1983
- CIK
- 0000318154
- Website
- amgen.com
- Similar Companies
- Business
- Amgen Inc. discovers, develops, manufactures and delivers innovative human therapeutics worldwide, focusing on biotechnology to treat serious illnesses in oncology, inflammation, cardiovascular disease, bone health, nephrology, neuroscience and rare diseases. Headquartered in Thousand Oaks, California, the company was founded in 1980 as Applied Molecular Genetics and pioneered the biotechnology industry with recombinant DNA technology. Amgen operates globally with manufacturing facilities in the United States, Ireland, Puerto Rico, Singapore, the Netherlands and other locations, serving patients through wholesalers and healthcare providers. The company's principal products include Prolia and Xgeva (denosumab) for osteoporosis and bone diseases; Enbrel (etanercept) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis and plaque psoriasis; Repatha (evolocumab) for hyperlipidemia; Otezla (apremilast) for psoriasis and psoriatic arthritis; Tepezza (teprotumumab) for Graves' ophthalmopathy; Evenity (romosozumab) for osteoporosis; Kyprolis (carfilzomib) for multiple myeloma; Nplate (romiplostim) for thrombocytopenia; Aranesp (darbepoetin alfa) for anemia; Neulasta (pegfilgrastim) and Neupogen (filgrastim) for neutropenia; Epogen (epoetin alfa) for anemia; Aimovig (erenumab) for migraine; Blincyto (blinatumomab) for acute lymphoblastic leukemia; Lumakras (sotorasib) for KRAS G12C-mutated non-small cell lung cancer; Tezspire (tezepelumab) for severe asthma; Vectibix (panitumumab) for colorectal cancer; Parsabiv (etelcalcetide) for secondary hyperparathyroidism; biosimilars such as Amjevita (adalimumab), Mvasi (bevacizumab), Kanjinti (trastuzumab), Riabni (rituximab) and Avsola (infliximab); and rare disease therapies including Krystexxa (pegloticase), Uplizna (inebilizumab) and Tavneos (avacopan). Amgen maintains a robust pipeline with 17 Phase III programs, including MariTide (maridebart cafraglutide), an investigational once-monthly anti-obesity therapy; Imdelltra (tarlatamab), a bispecific T-cell engager for extensive-stage small cell lung cancer; and advancements in oncology, cardiovascular and rare disease areas. Recent developments include major manufacturing expansions with a $650 million investment at its Juncos, Puerto Rico facility announced in September 2025 to enhance biologics production and create nearly 750 jobs; a $900 million expansion at its New Albany, Ohio biomanufacturing plant in April 2025; a $600 million Center for Science and Innovation at its Thousand Oaks headquarters broken ground in October 2025; and a $1 billion project at its Holly Springs, North Carolina site. In August 2025, Royalty Pharma acquired a royalty interest in Amgen's Imdelltra from BeOne Medicines for $885 million upfront. The company strengthened its portfolio through acquisitions including Horizon Therapeutics for $27.8 billion in 2023 adding Tepezza, Krystexxa and Uplizna; ChemoCentryx for $3.7 billion in 2022 adding Tavneos; and others such as Otezla from Celgene in 2019. Amgen continues collaborations like those with Kyowa Kirin, AstraZeneca and Generate Biomedicines, while advancing AI partnerships with Amazon Web Services for drug discovery announced in 2023.
AMGN DCF Analysis: Intrinsic Value $292 vs Price $355
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
Drugmakers race to find a place in the next wave of obesity drugs
Amgen taps research firm to reassess Tavneos data
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
Amgen Inc. (AMGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Amgen Eyes 2026 ‘Springboard' as Growth Drugs Offset Patent Pressure
Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
The Smartest Dividend ETF to Buy With $1,000 Right Now -- and It's Up 19% in 2026
Amgen: A Biotech Giant's Path to Recovery and Growth
Amgen: Time For An Upgrade? Yes, I Think So
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen Inc. (AMGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript